Gulcan Guntas

Prof. Dr. Gulcan Guntas

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2013 in Scandinavian Journal of Clinical and Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
GGGulcan Guntas
Gulcan Guntas
DKDildar Konukoglu
Dildar Konukoglu
EKEDA MERVE KURTULUŞ
EDA MERVE KURTULUŞ
HIHulya Irmak
Hulya Irmak
MBMurat Bolayirli
Murat Bolayirli
HUHafize Uzun
Hafize Uzun
Background. We investigated the ischemia-modified albumin (IMA), advanced oxidation protein products (AOPPs), prooxidants–antioxidants balance (PAB), and ferric reducing antioxidant power (FRAP) concentrations in patients with impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and diabetes mellitus (DM) and compared the results to those of normoglycemic individuals at baseline and 2 hours after glucose loading. Methods. An oral glucose tolerance test was performed on age-matched subjects (n = 110) with a body mass index (BMI) < 27 kg/m2. Subjects were categorized as normoglycemic (n = 35), IFG (n = 25), IGT (n = 30) and DM (n = 20) according to the WHO criteria. The IMA, AOPP, PAB, FRAP concentrations were determined by colorimetric methods. Results. At baseline, the AOPP concentrations were significantly higher in subjects with IFG and DM compared to normoglycemic subjects (p < 0.01 for all cases). The IFG, IGT and DM patients had a significantly higher IMA at baseline when compared with the normoglycemic individuals (p < 0.001 for all cases). The IMA in IFG subjects was significantly elevated (p < 0.05), while in DM patients, the IMA was significantly decreased (p < 0.001) after glucose loading with respect to baseline concentrations. Following glucose loading, the PAB was significantly decreased from baseline concentrations in normoglycemic individuals (p < 0.001) and in the IFG (p < 0.001) and IGT (p < 0.001) patients. Conclusion. In subjects with impaired glucose metabolism, the hyperglycemia is associated with increased IMA, AOPP and PAB concentrations. Increased IMA in subjects with IFG and decreased FRAP concentrations in subjects with IGT after glucose loading suggests that an increase in glucose concentrations can lead to tissue damage by increasing oxidative stress.

1 August 2013 in Clinical Biochemistry
Verified
Journal Article
Closed access
SDSermin Duran
Sermin Duran
IDIlyas Duran
Ilyas Duran
FKFatma Asuman Orçun Kaptanagası
Fatma Asuman Orçun Kaptanagası
FNFiliz Nartop
Filiz Nartop
HCHilmi Ciftci
Hilmi Ciftci
GGGulcan Guntas
Gulcan Guntas

Verified
Journal Article
Open access
PDF file
MEMine Huryasar Eskici
Mine Huryasar Eskici
NBNilgun Basaran
Nilgun Basaran
MGMukaddes Goker
Mukaddes Goker
BABuse Akyol
Buse Akyol
GGGulcan Guntas
Gulcan Guntas
Background: Asthma is a heterogeneous chronic inflammatory airway disease characterized by recurrent exacerbations and variable airflow limitation. Epithelial-derived alarmins, particularly interleukin-33 (IL-33) and its receptor ST2, play key roles in type 2 inflammation. The soluble form of ST2 (sST2) acts as a decoy receptor regulating IL-33 signaling. Vitamin D is an important immunomodulator influencing airway inflammation, but its interaction with the IL-33/ST2 pathway remains unclear. Objective: To evaluate the association between serum IL-33, sST2, and 25-hydroxyvitamin D [25(OH)D] levels with asthma severity and exacerbation status, and to assess their potential as clinical biomarkers. Methods: This study enrolled 52 adult asthma patients (27 experiencing exacerbation and 25 in remission) and 28 healthy controls. Serum levels of IL-33 and sST2 were measured using enzyme-linked immunosorbent assays, while 25(OH)D concentrations were determined via electrochemiluminescence immunoassay. Results: Serum sST2 levels were significantly higher and 25(OH)D levels significantly lower in asthma patients compared with controls (p < 0.000 for both). Serum IL-33 levels did not differ significantly between groups (p > 0.05). During exacerbation, sST2 levels were markedly elevated compared with remission (p < 0.001), whereas vitamin D levels were significantly reduced (p = 0.038). A significant negative correlation was identified between sST2 and 25(OH)D (r = −0.333, p = 0.016). Conclusions: The presence of asthma and the severity of exacerbations are associated with elevated circulating sST2 levels and reduced vitamin D levels. These findings suggest a regulatory interaction between vitamin D and the IL-33/ST2 axis in airway inflammation and indicate that targeting this axis could be a potential therapeutic strategy.

15 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MAmaide hacer Alagoz
maide hacer Alagoz
MAMine Adas
Mine Adas
YGYasemin Gokden
Yasemin Gokden
GGGulcan Guntas
Gulcan Guntas
Background/Objectives: Oxidative endothelial injury and vitamin D deficiency have independently been implicated in diabetic vascular complications, yet their distribution across the glycemic spectrum, from normoglycemia through prediabetes to established type 2 diabetes, has not been systematically characterised. This study aimed to evaluate serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) and 25-hydroxyvitamin D3 [25(OH)D3] levels across the glycemic spectrum and to examine their associations with microvascular complications and metabolic parameters in prediabetic individuals and patients with type 2 diabetes mellitus (T2DM). Methods: In this prospectively recruited cross-sectional study, 80 adults were enrolled: 26 healthy controls, 27 prediabetic individuals, and 27 T2DM patients. Serum sLOX-1 was quantified by enzyme-linked immunosorbent assay (ELISA) and 25(OH)D3 by liquid chromatography–tandem mass spectrometry (LC-MS/MS). Between-group comparisons were performed using the Kruskal–Wallis test with Dunn’s post hoc correction. Spearman’s rank correlation and binary logistic regression were applied to examine associations with metabolic and microvascular parameters. Results: Serum sLOX-1 was significantly elevated in both prediabetic (median 10.75 ng/mL; p = 0.0397) and T2DM (8.83 ng/mL; p = 0.0209) groups compared to controls (3.50 ng/mL) in unadjusted analyses. After adjustment for age and body mass index (BMI) by quantile regression, the elevation persisted in the prediabetic group (adjusted ratio of medians = 2.91, p = 0.040) but was substantially attenuated and no longer significant in the T2DM group (ratio = 1.81, p = 0.265). Serum 25(OH)D3 was significantly lower in the T2DM group than in prediabetic individuals (12.11 vs. 22.69 ng/mL; p = 0.0024) but did not decline progressively across the glycemic spectrum; vitamin D deficiency (<20 ng/mL) was present in 78% of T2DM patients. In binary logistic regression (five predictors, events per variable (EPV) = 5.4), 25(OH)D3 (odds ratio (OR) = 0.922, p = 0.020) and log-transformed urinary albumin-to-creatinine ratio (logUACR; OR = 4.014, p = 0.001) were independently associated with T2DM status after adjustment for age and waist circumference, while sLOX-1 was not significant (OR = 1.058, p = 0.136). In unadjusted analyses, sLOX-1 correlated positively with waist circumference and glycated hemoglobin (HbA1c); both associations were no longer statistically significant after age adjustment. Conclusions: These findings show that sLOX-1 is elevated at the prediabetic stage independently of age and BMI, whereas the elevation in established T2DM was not robust to covariate adjustment. Lower 25(OH)D3 concentrations were associated with T2DM status in logistic regression, but this association was not significant when the reference group was restricted to normoglycaemic controls, indicating that the finding reflects the contrast between T2DM and prediabetic groups rather than a generalised pattern across the glycaemic spectrum. The two biomarkers were not significantly correlated with one another. Given the cross-sectional design, low EPV, and exploratory nature of all analyses, prospective validation in larger age-matched cohorts is required.

26 October 2026 in Cerrahpasa Medical Journal
Verified
Journal Article
Open access
PDF file
MIMusab Işık
Musab Işık
GŞGülderen Şahin
Gülderen Şahin
SBSema Bolkent
Sema Bolkent
MYMuhittin Onur Yaman
Muhittin Onur Yaman
GTGamze Tanrıverdi
Gamze Tanrıverdi
IGIbrahim Guner
Ibrahim Guner
Objective: This study aimed to evaluate the hepatoprotective effects of thymosin β4 (Tβ4) administered at different time points (before ischemia and before reperfusion) in an experimental rat model of hepatic ischemia–reperfusion injury (HIRI). Methods: Thirty-two Sprague–Dawley rats were randomly divided into 4 experimental groups (n = 8 per group): C, IR, Tβ4/IR, and I/Tβ4/R. Ischemia was induced by occlusion of the infrarenal abdominal aorta for 90 minutes, followed by 180 minutes of reperfusion. Oxidative stress (PAB, FRAP, MDA, LOOH, SOD, GSH), inflammatory biomarkers (TNF-α, IL-6, IL-1β, NF-κB), apoptosis- and tissue injury–related biomarkers (caspase-9, MMP-9, hyaluronic acid, nitric oxide), serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities, and histopathological changes were evaluated. Results: Hepatic IR significantly increased oxidative stress, lipid peroxidation, inflammatory cytokines, NF-κB activation, apoptosis-related and tissue injury–related biomarkers, nitric oxide, serum AST/ALT activities, and histopathological injury, while significantly reducing antioxidant capacity (all P < .05). Both Tβ4 treatment protocols attenuated these alterations, with improvements in oxidative stress-related parameters, inflammatory responses, apoptosis-related markers, tissue injury–related biomarkers, liver enzyme levels, and histopathological findings. Both Tβ4/IR and I/Tβ4/R groups showed improvements compared with the IR group. Conclusion: Thymosin β4 demonstrated hepatoprotective effects against HIRI, as evidenced by improvements in oxidative stress, inflammatory, apoptosis-related, biochemical and histopathological parameters. These findings support further investigation of Tβ4 as a potential hepatoprotective agent in experimental HIRI, including evaluation of different administration time points. Cite this article as: Işık M, Şahin G, Bolkent S, et al. Thymosin β4 protects against hepatic ischemia–reperfusion injury through multi-target mechanisms. Cerrahpaşa Med J 2026, 50, 0106, doi: 10.5152/cjm.2026.26106